遺伝子治療薬のグローバル市場展望 2023年-2029年:ウイルス遺伝子導入システム、非ウイルス遺伝子導入システム

【英語タイトル】Gene-based Therapy Medicinal Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料(MMG23DC14340)・商品コード:MMG23DC14340
・発行会社(調査会社):Market Monitor Global
・発行日:2023年12月
・ページ数:62
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の遺伝子治療薬市場規模と予測を収録しています。・世界の遺伝子治療薬市場:売上、2018年-2023年、2024年-2029年
・世界の遺伝子治療薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の遺伝子治療薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ウイルス遺伝子導入システム」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

遺伝子治療薬のグローバル主要企業は、Biogen、 Novartis、 Gilead Sciences、 Sarepta Therapeutics、 Alnylam Pharmaceuticals、 Amgen、 Spark Therapeutics、 Akcea Therapeutics、 Sunway Biotech、 SIBIONO、 AnGes、 Orchard Therapeutics、 Human Stem Cells Instituteなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、遺伝子治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の遺伝子治療薬市場:タイプ別、2018年-2023年、2024年-2029年
世界の遺伝子治療薬市場:タイプ別市場シェア、2022年
・ウイルス遺伝子導入システム、非ウイルス遺伝子導入システム

世界の遺伝子治療薬市場:用途別、2018年-2023年、2024年-2029年
世界の遺伝子治療薬市場:用途別市場シェア、2022年
・神経疾患、癌、その他

世界の遺伝子治療薬市場:地域・国別、2018年-2023年、2024年-2029年
世界の遺伝子治療薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における遺伝子治療薬のグローバル売上、2018年-2023年
・主要企業における遺伝子治療薬のグローバル売上シェア、2022年
・主要企業における遺伝子治療薬のグローバル販売量、2018年-2023年
・主要企業における遺伝子治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Biogen、 Novartis、 Gilead Sciences、 Sarepta Therapeutics、 Alnylam Pharmaceuticals、 Amgen、 Spark Therapeutics、 Akcea Therapeutics、 Sunway Biotech、 SIBIONO、 AnGes、 Orchard Therapeutics、 Human Stem Cells Institute

*************************************************************

・調査・分析レポートの概要
遺伝子治療薬市場の定義
市場セグメント
世界の遺伝子治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の遺伝子治療薬市場規模
世界の遺伝子治療薬市場規模:2022年 VS 2029年
世界の遺伝子治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの遺伝子治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の遺伝子治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:ウイルス遺伝子導入システム、非ウイルス遺伝子導入システム
遺伝子治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:神経疾患、癌、その他
遺伝子治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別遺伝子治療薬市場規模 2022年と2029年
地域別遺伝子治療薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Biogen、 Novartis、 Gilead Sciences、 Sarepta Therapeutics、 Alnylam Pharmaceuticals、 Amgen、 Spark Therapeutics、 Akcea Therapeutics、 Sunway Biotech、 SIBIONO、 AnGes、 Orchard Therapeutics、 Human Stem Cells Institute
...

This research report provides a comprehensive analysis of the Gene-based Therapy Medicinal market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Gene-based Therapy Medicinal market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Gene-based Therapy Medicinal, challenges faced by the industry, and potential opportunities for market players.
The global Gene-based Therapy Medicinal market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Gene-based Therapy Medicinal market presents opportunities for various stakeholders, including Neurological Diseases, Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Gene-based Therapy Medicinal market. Additionally, the growing consumer demand present avenues for market expansion.
The global Gene-based Therapy Medicinal market was valued at US$ 8548.6 million in 2022 and is projected to reach US$ 46680 million by 2029, at a CAGR of 27.4% during the forecast period.
The gene-based therapy medicinal market is driven by the potential for revolutionary treatments by targeting genetic disorders at their source. These therapies offer hope for conditions with no existing cures. However, a significant challenge is the complexity of gene-based therapies and the need for rigorous clinical trials to prove safety and efficacy. Regulatory approvals and high development costs pose challenges for manufacturers. Additionally, market competition and pricing concerns necessitate a balance between accessibility and recovering research and development investments. The gene-based therapy market holds promise but faces hurdles in delivering groundbreaking treatments while addressing scientific, regulatory, and economic challenges.
Key Features:
The research report on the Gene-based Therapy Medicinal market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Gene-based Therapy Medicinal market.
Market Overview: The report provides a comprehensive overview of the Gene-based Therapy Medicinal market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Viral Gene Delivery System, Non-viral Gene Delivery System), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Gene-based Therapy Medicinal market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Gene-based Therapy Medicinal market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Gene-based Therapy Medicinal market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Gene-based Therapy Medicinal market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Gene-based Therapy Medicinal market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Gene-based Therapy Medicinal market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Gene-based Therapy Medicinal, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Gene-based Therapy Medicinal market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Gene-based Therapy Medicinal market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Viral Gene Delivery System
Non-viral Gene Delivery System
Market segment by Application
Neurological Diseases
Cancer
Other
Global Gene-based Therapy Medicinal Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gene-based Therapy Medicinal, market overview.
Chapter 2: Global Gene-based Therapy Medicinal market size in revenue.
Chapter 3: Detailed analysis of Gene-based Therapy Medicinal company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gene-based Therapy Medicinal in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Gene-based Therapy Medicinal Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gene-based Therapy Medicinal Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gene-based Therapy Medicinal Overall Market Size
2.1 Global Gene-based Therapy Medicinal Market Size: 2022 VS 2029
2.2 Global Gene-based Therapy Medicinal Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gene-based Therapy Medicinal Players in Global Market
3.2 Top Global Gene-based Therapy Medicinal Companies Ranked by Revenue
3.3 Global Gene-based Therapy Medicinal Revenue by Companies
3.4 Top 3 and Top 5 Gene-based Therapy Medicinal Companies in Global Market, by Revenue in 2022
3.5 Global Companies Gene-based Therapy Medicinal Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gene-based Therapy Medicinal Players in Global Market
3.6.1 List of Global Tier 1 Gene-based Therapy Medicinal Companies
3.6.2 List of Global Tier 2 and Tier 3 Gene-based Therapy Medicinal Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Gene-based Therapy Medicinal Market Size Markets, 2022 & 2029
4.1.2 Viral Gene Delivery System
4.1.3 Non-viral Gene Delivery System
4.2 By Type – Global Gene-based Therapy Medicinal Revenue & Forecasts
4.2.1 By Type – Global Gene-based Therapy Medicinal Revenue, 2018-2023
4.2.2 By Type – Global Gene-based Therapy Medicinal Revenue, 2024-2029
4.2.3 By Type – Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Gene-based Therapy Medicinal Market Size, 2022 & 2029
5.1.2 Neurological Diseases
5.1.3 Cancer
5.1.4 Other
5.2 By Application – Global Gene-based Therapy Medicinal Revenue & Forecasts
5.2.1 By Application – Global Gene-based Therapy Medicinal Revenue, 2018-2023
5.2.2 By Application – Global Gene-based Therapy Medicinal Revenue, 2024-2029
5.2.3 By Application – Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Gene-based Therapy Medicinal Market Size, 2022 & 2029
6.2 By Region – Global Gene-based Therapy Medicinal Revenue & Forecasts
6.2.1 By Region – Global Gene-based Therapy Medicinal Revenue, 2018-2023
6.2.2 By Region – Global Gene-based Therapy Medicinal Revenue, 2024-2029
6.2.3 By Region – Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Gene-based Therapy Medicinal Revenue, 2018-2029
6.3.2 US Gene-based Therapy Medicinal Market Size, 2018-2029
6.3.3 Canada Gene-based Therapy Medicinal Market Size, 2018-2029
6.3.4 Mexico Gene-based Therapy Medicinal Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Gene-based Therapy Medicinal Revenue, 2018-2029
6.4.2 Germany Gene-based Therapy Medicinal Market Size, 2018-2029
6.4.3 France Gene-based Therapy Medicinal Market Size, 2018-2029
6.4.4 U.K. Gene-based Therapy Medicinal Market Size, 2018-2029
6.4.5 Italy Gene-based Therapy Medicinal Market Size, 2018-2029
6.4.6 Russia Gene-based Therapy Medicinal Market Size, 2018-2029
6.4.7 Nordic Countries Gene-based Therapy Medicinal Market Size, 2018-2029
6.4.8 Benelux Gene-based Therapy Medicinal Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Gene-based Therapy Medicinal Revenue, 2018-2029
6.5.2 China Gene-based Therapy Medicinal Market Size, 2018-2029
6.5.3 Japan Gene-based Therapy Medicinal Market Size, 2018-2029
6.5.4 South Korea Gene-based Therapy Medicinal Market Size, 2018-2029
6.5.5 Southeast Asia Gene-based Therapy Medicinal Market Size, 2018-2029
6.5.6 India Gene-based Therapy Medicinal Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Gene-based Therapy Medicinal Revenue, 2018-2029
6.6.2 Brazil Gene-based Therapy Medicinal Market Size, 2018-2029
6.6.3 Argentina Gene-based Therapy Medicinal Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Gene-based Therapy Medicinal Revenue, 2018-2029
6.7.2 Turkey Gene-based Therapy Medicinal Market Size, 2018-2029
6.7.3 Israel Gene-based Therapy Medicinal Market Size, 2018-2029
6.7.4 Saudi Arabia Gene-based Therapy Medicinal Market Size, 2018-2029
6.7.5 UAE Gene-based Therapy Medicinal Market Size, 2018-2029
7 Gene-based Therapy Medicinal Companies Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Gene-based Therapy Medicinal Major Product Offerings
7.1.4 Biogen Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Gene-based Therapy Medicinal Major Product Offerings
7.2.4 Novartis Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Company Summary
7.3.2 Gilead Sciences Business Overview
7.3.3 Gilead Sciences Gene-based Therapy Medicinal Major Product Offerings
7.3.4 Gilead Sciences Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.3.5 Gilead Sciences Key News & Latest Developments
7.4 Sarepta Therapeutics
7.4.1 Sarepta Therapeutics Company Summary
7.4.2 Sarepta Therapeutics Business Overview
7.4.3 Sarepta Therapeutics Gene-based Therapy Medicinal Major Product Offerings
7.4.4 Sarepta Therapeutics Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.4.5 Sarepta Therapeutics Key News & Latest Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Company Summary
7.5.2 Alnylam Pharmaceuticals Business Overview
7.5.3 Alnylam Pharmaceuticals Gene-based Therapy Medicinal Major Product Offerings
7.5.4 Alnylam Pharmaceuticals Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.5.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.6 Amgen
7.6.1 Amgen Company Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Gene-based Therapy Medicinal Major Product Offerings
7.6.4 Amgen Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.6.5 Amgen Key News & Latest Developments
7.7 Spark Therapeutics
7.7.1 Spark Therapeutics Company Summary
7.7.2 Spark Therapeutics Business Overview
7.7.3 Spark Therapeutics Gene-based Therapy Medicinal Major Product Offerings
7.7.4 Spark Therapeutics Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.7.5 Spark Therapeutics Key News & Latest Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Company Summary
7.8.2 Akcea Therapeutics Business Overview
7.8.3 Akcea Therapeutics Gene-based Therapy Medicinal Major Product Offerings
7.8.4 Akcea Therapeutics Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.8.5 Akcea Therapeutics Key News & Latest Developments
7.9 Sunway Biotech
7.9.1 Sunway Biotech Company Summary
7.9.2 Sunway Biotech Business Overview
7.9.3 Sunway Biotech Gene-based Therapy Medicinal Major Product Offerings
7.9.4 Sunway Biotech Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.9.5 Sunway Biotech Key News & Latest Developments
7.10 SIBIONO
7.10.1 SIBIONO Company Summary
7.10.2 SIBIONO Business Overview
7.10.3 SIBIONO Gene-based Therapy Medicinal Major Product Offerings
7.10.4 SIBIONO Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.10.5 SIBIONO Key News & Latest Developments
7.11 AnGes
7.11.1 AnGes Company Summary
7.11.2 AnGes Business Overview
7.11.3 AnGes Gene-based Therapy Medicinal Major Product Offerings
7.11.4 AnGes Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.11.5 AnGes Key News & Latest Developments
7.12 Orchard Therapeutics
7.12.1 Orchard Therapeutics Company Summary
7.12.2 Orchard Therapeutics Business Overview
7.12.3 Orchard Therapeutics Gene-based Therapy Medicinal Major Product Offerings
7.12.4 Orchard Therapeutics Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.12.5 Orchard Therapeutics Key News & Latest Developments
7.13 Human Stem Cells Institute
7.13.1 Human Stem Cells Institute Company Summary
7.13.2 Human Stem Cells Institute Business Overview
7.13.3 Human Stem Cells Institute Gene-based Therapy Medicinal Major Product Offerings
7.13.4 Human Stem Cells Institute Gene-based Therapy Medicinal Revenue in Global Market (2018-2023)
7.13.5 Human Stem Cells Institute Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Gene-based Therapy Medicinal Market Opportunities & Trends in Global Market
Table 2. Gene-based Therapy Medicinal Market Drivers in Global Market
Table 3. Gene-based Therapy Medicinal Market Restraints in Global Market
Table 4. Key Players of Gene-based Therapy Medicinal in Global Market
Table 5. Top Gene-based Therapy Medicinal Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Gene-based Therapy Medicinal Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Gene-based Therapy Medicinal Revenue Share by Companies, 2018-2023
Table 8. Global Companies Gene-based Therapy Medicinal Product Type
Table 9. List of Global Tier 1 Gene-based Therapy Medicinal Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gene-based Therapy Medicinal Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Gene-based Therapy Medicinal Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Gene-based Therapy Medicinal Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Gene-based Therapy Medicinal Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Gene-based Therapy Medicinal Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Gene-based Therapy Medicinal Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Gene-based Therapy Medicinal Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Gene-based Therapy Medicinal Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Gene-based Therapy Medicinal Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Gene-based Therapy Medicinal Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Gene-based Therapy Medicinal Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Gene-based Therapy Medicinal Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Gene-based Therapy Medicinal Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Gene-based Therapy Medicinal Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Gene-based Therapy Medicinal Revenue, (US$, Mn), 2024-2029
Table 30. Biogen Company Summary
Table 31. Biogen Gene-based Therapy Medicinal Product Offerings
Table 32. Biogen Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 33. Biogen Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis Gene-based Therapy Medicinal Product Offerings
Table 36. Novartis Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis Key News & Latest Developments
Table 38. Gilead Sciences Company Summary
Table 39. Gilead Sciences Gene-based Therapy Medicinal Product Offerings
Table 40. Gilead Sciences Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 41. Gilead Sciences Key News & Latest Developments
Table 42. Sarepta Therapeutics Company Summary
Table 43. Sarepta Therapeutics Gene-based Therapy Medicinal Product Offerings
Table 44. Sarepta Therapeutics Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 45. Sarepta Therapeutics Key News & Latest Developments
Table 46. Alnylam Pharmaceuticals Company Summary
Table 47. Alnylam Pharmaceuticals Gene-based Therapy Medicinal Product Offerings
Table 48. Alnylam Pharmaceuticals Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 49. Alnylam Pharmaceuticals Key News & Latest Developments
Table 50. Amgen Company Summary
Table 51. Amgen Gene-based Therapy Medicinal Product Offerings
Table 52. Amgen Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 53. Amgen Key News & Latest Developments
Table 54. Spark Therapeutics Company Summary
Table 55. Spark Therapeutics Gene-based Therapy Medicinal Product Offerings
Table 56. Spark Therapeutics Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 57. Spark Therapeutics Key News & Latest Developments
Table 58. Akcea Therapeutics Company Summary
Table 59. Akcea Therapeutics Gene-based Therapy Medicinal Product Offerings
Table 60. Akcea Therapeutics Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 61. Akcea Therapeutics Key News & Latest Developments
Table 62. Sunway Biotech Company Summary
Table 63. Sunway Biotech Gene-based Therapy Medicinal Product Offerings
Table 64. Sunway Biotech Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 65. Sunway Biotech Key News & Latest Developments
Table 66. SIBIONO Company Summary
Table 67. SIBIONO Gene-based Therapy Medicinal Product Offerings
Table 68. SIBIONO Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 69. SIBIONO Key News & Latest Developments
Table 70. AnGes Company Summary
Table 71. AnGes Gene-based Therapy Medicinal Product Offerings
Table 72. AnGes Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 73. AnGes Key News & Latest Developments
Table 74. Orchard Therapeutics Company Summary
Table 75. Orchard Therapeutics Gene-based Therapy Medicinal Product Offerings
Table 76. Orchard Therapeutics Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 77. Orchard Therapeutics Key News & Latest Developments
Table 78. Human Stem Cells Institute Company Summary
Table 79. Human Stem Cells Institute Gene-based Therapy Medicinal Product Offerings
Table 80. Human Stem Cells Institute Gene-based Therapy Medicinal Revenue (US$, Mn) & (2018-2023)
Table 81. Human Stem Cells Institute Key News & Latest Developments
List of Figures
Figure 1. Gene-based Therapy Medicinal Segment by Type in 2022
Figure 2. Gene-based Therapy Medicinal Segment by Application in 2022
Figure 3. Global Gene-based Therapy Medicinal Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Gene-based Therapy Medicinal Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Gene-based Therapy Medicinal Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gene-based Therapy Medicinal Revenue in 2022
Figure 8. By Type - Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 9. By Application - Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 10. By Type - Global Gene-based Therapy Medicinal Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 12. By Application - Global Gene-based Therapy Medicinal Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 14. By Region - Global Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 15. By Country - North America Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 16. US Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 20. Germany Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 21. France Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 28. China Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 32. India Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 34. Brazil Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Gene-based Therapy Medicinal Revenue Market Share, 2018-2029
Figure 37. Turkey Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Gene-based Therapy Medicinal Revenue, (US$, Mn), 2018-2029
Figure 41. Biogen Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Gilead Sciences Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sarepta Therapeutics Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Alnylam Pharmaceuticals Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Amgen Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Spark Therapeutics Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Akcea Therapeutics Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Sunway Biotech Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. SIBIONO Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. AnGes Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Orchard Therapeutics Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Human Stem Cells Institute Gene-based Therapy Medicinal Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



★調査レポート[遺伝子治療薬のグローバル市場展望 2023年-2029年:ウイルス遺伝子導入システム、非ウイルス遺伝子導入システム] (コード:MMG23DC14340)販売に関する免責事項を必ずご確認ください。
★調査レポート[遺伝子治療薬のグローバル市場展望 2023年-2029年:ウイルス遺伝子導入システム、非ウイルス遺伝子導入システム]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆